What is driving the pre-market move in 6600.HK

Early buying lifted SciClone to HK$92.00 on 03 Jan 2026 after a rebound from year lows and a move above the 50/200-day averages at HK$77.23. Volume was 706,800.00, below average, suggesting the move may be momentum-driven rather than broad-based

How does SciClone’s valuation compare with Healthcare peers

SciClone’s TTM P/E is 45.27 and price-to-sales is 16.50, both above Healthcare sector averages (P/E ~29.54), indicating a premium valuation that could compress if earnings disappoint

What are reasonable price targets for a bounce trade

Tactical targets are HK$95.00 for an initial exit and HK$110.00 as a secondary target. Use a protective stop below HK$77.35 to limit downside risk on a failed bounce

What does the Meyka AI grade mean for investors

Meyka AI grades 6600.HK B+ (score 70.27, suggestion BUY) based on multi-factor analysis. Grades inform risk/reward but are not guarantees; investors should conduct their own due diligence

HK Stocks

SciClone 6600.HK pre-market HK$92.00 03 Jan 2026: oversold bounce signal

ByHuzaifa Zahoor January 3, 2026January 3, 2026

The 6600.HK stock shows an oversold bounce setup in pre-market trading on 03 Jan 2026 after a sharp intraday lift to HK$92.00. SciClone Pharmaceuticals (6600.HK) is trading on the HKSE in Hong Kong with a quoted gain of 14.07% versus the previous close of HK$80.65 and volume at 706800.00. The move has pushed the price above the 50-day and 200-day averages at HK$77.23, creating a technical recovery opportunity that warrants a data-driven trading plan